Fig. 6

Decreased TMPRSS2 levels upon ruxolitinib treatment. A: Western blot analyses were performed using antibodies targeting TMPRSS2 and ACE2 in cells treated with 300 nM of ruxolitinib. B, C: Correlation plots were generated for TMPRSS2 with JAK1 (B) and JAK2 (C) using the MCF-7 dataset and R2 Genomics. D: Reduction of TMPRSS2 by siTMPRSS2 delivered via lipid nanoparticles was evaluated by Western blot analysis with antibodies against TMPRSS2 in MDA-MB-468 cells. E, F: Silencing of TMPRSS2 resulted in a significant reduction in HLA-I (E) and PD-L1 (F) surface expression assessed by flow cytometry